×

Race Oncology Ltd

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein.

Spotlight Videos

A precision oncology company
All Race Oncology Ltd Content

News

A precision oncology company

Presenter - Daniel Tillett - Chief Scientific Officer & Executive Director - Race Oncology is a precision oncology company with a Phase II/III cancer drug called Bisantrene. The drug is a potent small molecule inhibitor of the Fat mass and obesity associated (FTO) protein.

Read More